Q-omics provides the consensus-scored KLK1 profile across patient tissues and cancer cell-line models. KLK1 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, KLK1 is differentially expressed in 14, with the highest sampling consensus in KIRP. Additionally, KLK1 RNA expression shows 13,773 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight KIRC, KIRP, and THYM as cancer lineages where KLK1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for KLK1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes KLK1 survival associations across molecular data types. KLK1 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (3) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible KLK1 RNA expression–survival associations across cancer types. High KLK1 expression shows unfavorable associations in KIRC and KIRP, but favorable associations in BRCA, ACC, SCLC and ESCA. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for KLK1 RNA expression.
This table summarizes KLK1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 2. The strongest signals are observed in KIRC for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for KLK1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. KLK1 shows lower tumor expression in KIRP, KIRC, COAD, THCA and BRCA and higher tumor expression in KICH. The KIRP box plot shows higher KLK1 RNA expression in normal versus tumor tissue (log2 FC = −4.026, t-test p < 0.001).
This table shows molecular features associated with KLK1 in patient tissues and cancer cell lines. In patient samples, KLK1 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, KLK1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUSC, while CRISPR and shRNA rows add functional-dependency signals in LARGE_INTESTINE and BONE.
